English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169182
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Differentiation stage of myeloma plasma cells: Biological and clinical significance

AuthorsPaiva, Bruno; Puig, Noemi; Cedena, Maria-Teresa; Jong, B. G. de; Ruiz, Y.; Rapado, Inmaculada; Martínez-López, Joaquín; Cordon, Lourdes; Alignani, Diego; Delgado, J. A.; Zelm, Menno C. van; Dongen, J. J. M. van; Pascual, M.; Agirre, Xavier; Prosper, Felipe; Martín-Subero, José Ignacio; Vidriales, Maria Belén; Gutiérrez, Norma Carmen; Hernández, M. Teresa CSIC; Oriol, Albert; Echeveste, María-Asunción; Gonzalez, Yolanda; Johnson, S. K.; Epstein, J.; Barlogie, B.; Morgan, Gareth J.; Orfao, Alberto CSIC ORCID ; Bladé, Joan; Mateos, Maria Victoria; Lahuerta, Juan José; San Miguel, Jesús F. CSIC ORCID
Issue Date2017
PublisherNature Publishing Group
CitationLeukemia 31(2): 382-392 (2017)
AbstractThe notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n=20) that the CD19-CD81 expression axis identifies three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, immunoglobulin-production, and phenotype, consistent with progressively increased differentiation from CD19+CD81+ into CD19-CD81+ and CD19-CD81- BMPCs. Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal BMPC counterparts, 59% had fully differentiated (CD19-CD81-) clones, 38% intermediate-differentiated (CD19-CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker for progression-free (HR: 1.7; P=0.005) and overall survival (HR: 2.1; P=0.006). Longitudinal comparison of diagnostic vs minimal-residual-disease samples (n=40) unraveled that in 20% of patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated PCs have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles.
Publisher version (URL)https://doi.org/10.1038/leu.2016.211
Identifiersdoi: 10.1038/leu.2016.211
e-issn: 1476-5551
issn: 0887-6924
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
diffemyelosig.pdf1,8 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.